Market Size
The Global Insulin Biosimilars Market reached US$ 2.5 billion in 2025 and is expected to reach US$ 6.0 billion by 2033, growing at a CAGR of 14.8% during the forecast period 2026-2033.
Biosimilars are equivalent to a reference biologic drug and are developed after the patent on the concerned biologic drug has passed. Biosimilar insulin is a biological replica of an actual insulin and there is rising interest in designing and utilizing them. Biosimilar insulins are more inexpensive compared to original developments therefore they offer the NHS with prospects around availability and expense of care.
Insulin Biosimilars Market Scope
| Metrics | Details |
| CAGR | 14.8% |
| Market Size Available for Years | 2023-2033 |
| Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product, Indication, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing Cases of Diabetes
The global market growth is expected to be boosted during the forecast period due to the increasing cases of diabetes mellitus. The World Health Organization (WHO) states that about 422 million individuals worldwide have diabetes, the bulk of whom are living in low- and middle-income countries, and over 1.5 million casualties are straight attributed to diabetes annually. Both the number of cases and the preponderance of diabetes have been steadily growing over the past few decades. Moreover, according to the International Diabetes Federation, IDF projections by 2045, one in eight adults, roughly 783 million individuals are expected to be living with diabetes, an upsurge of 46%. Above 90% of individuals with diabetes have type 2 diabetes, which is caused by socio-economic, demographic, environmental, and genetic factors. Again, Diabetes Australia identifies diabetes as the fastest-growing chronic disorder globally. The number of individuals with type 2 diabetes is increasing in each nation, and in 2021, diabetes induced 6.7 million casualties globally.
Additionally, the growing geriatric population and increased research activities are among the additional factors boosting the global market during the forecast period.
Insulin Side Effects
However, the global market growth for insulin biosimialr is being hindered during the forecast period owing to its side effects. The typical side effects of insulin include hypoglycemia (low blood glucose), injection site allergies, and weight increase. Infrequent side effects of insulin include lipodystrophy (abnormal fat distribution) and swelling in the arms and legs. Further, the presence of stringent regulatory bodies and high therapy cost are among the additional factors slowing the global market growth during the forecast period.
Insulin Biosimilars Market Segmentation
The global insulin biosimilars market is segmented based on product, indication, distribution channel and region.
Long-Acting Insulin Biosimilars Product Type Segment is Expected to Dominate Market
During the forecast period, the segment of long-acting insulin biosimilars is expected to dominate the global market, due to the increasing product introduction and approval. For example, Eli Lilly and Company introduced its insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), on the US market in April 2023, making it the second interchangeable insulin biosimilar to become commercially obtainable to American patients with diabetes. Moreover, in November 2022, The FDA approved Rezvoglar, a biosimilar for Lantus (insulin glargine) that was originally approved in December 2021, for an interchangeability designation, letting the product to be swapped for the reference product at the pharmacy station without needing physician permission.
Additionally, in July 2021, the US Food and Drug Administration approved the first interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), which is both biosimilar to and interchangeable with its reference product Lantus (insulin glargine), a long-acting insulin analog, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.
Global Insulin Biosimilars Market Geographical Share
North America is Expected to Dominate the Global Market
The North America market is expected to dominate the global market during the forecast period due to rising initiatives to produce cost-effective insulin and increasing market developments. For instance, California's governor lately marked the state's budget for 2022 and 2023, which included a $100 million budget for designing low-cost insulin to improve availability and affordability of insulin in the state. The budget included $100.7 million for the CalRX Biosimilar Insulin Initiative in 2022-2023, heeded by $700,000 yearly between 2023-2024 and 2025-2026.
Of the budget, $50 million intended move to the expansion of low-cost interchangeable biosimilar insulin developments, $50 million to an insulin manufacturing establishment established in California, and $700,000 yearly to state operations. Furthermore, in September 2023, Meitheal Pharmaceuticals, a fully incorporated biopharmaceutical corporation based in Chicago, formed an exclusive licensing deal with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars - insulin aspart, insulin lispro, and insulin glargine in the US. NKF has undivided development and commercial privileges for the three combinations from associate THDB and plans for Meitheal to commercialize such developments in the US.
Key Developments
- In November 2022, Biocon Biologics Ltd., an associate of Biocon Ltd. completed the acquisition of the multinational biosimilars business of its partner Viatris Inc. Biocon Biologics and Viatris have acquired all relevant permissions from essential multinational regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors.
- In October 2021, Sandoz’ association with China’s Gan & Lee covering three biosimilar insulin products persists to create advancement, with the closing of a couple of Phase III trials concerning a suggested biosimilar to Lantus (insulin glargine).
- In May 2020, the Committee for Medicinal Products for Human Use (CHMP) Europe granted marketing authorization for a biosimilar insulin aspart formulated by Sanofi and planned for the therapy of diabetes mellitus.
Market Major Players
The major global players in the market include Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Eli Lilly & Co., NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG, Amphastar Pharmaceuticals, Inc. and Julphar Gulf Pharmaceutical Industries.
Why Purchase the Report?
- To visualize the global insulin biosimilars market segmentation based on product, indication, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of insulin biosimilars market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key product of all the major players.
The global insulin biosimilars market report would provide approximately 61 tables, 56 figures and 180 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
